-
FHU Mosaic²
2025-2029 Web site : https://fhu-mosaic.com MOSAIC² objective is to elucidate cancer heterogeneity across various types of cancers, and to contribute to the advanced understanding of the intricate interplay between tumor and host environment
-
FHU “FOR LIFE”
FédératiOn de Recherche pour la mise en Lumière par l’Imagerie du FoEtus Congenital anomalies affect 1% to 2% of pregnancies. Placental dysfunction also complicates 3% to 10% of pregnancies, often
-
MALDIBANK
Multi-domain Open MALDI Spectra Archive for Identification of Microorganisms 2025-2029 Funding: European HORIZON Research and Innovation Actions Web site: https://cordis.europa.eu/project/id/101188201 Microbes are essential to life, yet their vast diversity remains
-
RXCIPHER
Start date: 2025 Funding: Sorbonne Université This project aims to improve drug database management by proposing an advanced structuring of drug information and further automation of the database construction. By
-
Trajectome
Funding: Inserm, program MESSIDORE (Méthodologie des Essais cliniques Innovants, Dispositifs, Outils et Recherches Exploitant les données de santé et biobanques) Starting date: 2025 Trajectome is a collaborative project between mental healthcare professionals
-
PARTAGES
2024-2027 Funding: Bpifrance The “PARTAGES” project, led by a consortium of 32 partners, including research laboratories, healthcare institutions, and deep tech companies, is a recipient of the France 2030 funding
-
INDICATE
2024-2029 Funding: European Union’s Digital Europe 2023 programme Web site: https://indicate-europe.eu/ Press release: https://indicate-europe.eu/news/launch-of-indicate-connecting-intensive-care-data-across-europe/ Linkedin: https://www.linkedin.com/company/indicate-eu X: https://x.com/IndicateEU INDICATE is a pioneering European initiative designed to enhance data access and sharing between intensive care units
-
PostGenAI@Paris
2024 – 2029 Funding : France 2030 Limics is a partner in the PostGenAI@Paris cluster, a project led by Sorbonne University, which was selected from among nine research centers in
-
Phares 2: Social media and pharmacovigilance
2024 – 2026 Funding: ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé) Title : A processing chain for social media data and its application to pharmacovigilance
-
RHU AI-Triomph
2024 – 2029 The hospital-university health research program (RHU) run by the ANR aims to support translational health and clinical research projects. The RHU AI-Triomph (Artificial Intelligence – clinical TRIals
-
SMeLT : Similarity Measure Learning for analogical Transfer
2023 – 2026 Funded by ANR https://smelt.irsan.eu/ The aim of SMeLT is to provide a methodology to learn a similarity measure that is optimized for a given analogical transfer task.Among
-
EUCAIM
2023 – 2026 European Commission: European Cancer Imaging Initiative https://www.eibir.org/projects/eucaim/ EUropean Federation for CAncer IMages (EUCAIM) is the cornerstone of the European Commission-initiated European Cancer Imaging Initiative, a flagship of Europe’s
-
Integrated cancer research site CURAMUS
2023 – 2028 Funded by the French National Cancer Institute (INCa) Accueil The SiRIC CURAMUS was accredited again in 2023 by the French National Cancer Institute (INCa) and led by
-
CDE.AI
2022 – 2028 ANR funding: Priority research program on Rare Diseases CDE.AI: Artificial Intelligence at the service of common data elements for rare diseases The BNDMR (Base de Données Maladies
-
Medication Review Support – ABiMed
2020 – 2024 Funded by ANR Decision support tools for medication review and polypharmacy management Polypharmacy is a major public health problem. It causes adverse events and drug-drug interactions, but
-
Smart Ultrasound in Obstetrics and Gynecology (SUOG)
2020 – 2024 EIT Health’s innovation programme Home SUOG Screening in early pregnancy for foetal abnormalities is an established part of routine care in Western countries. If the screening identifies an
-
Open resources and methodologies for the detection of drug-drug interaction in clinical data warehouses – REMIAMES
2019 – 2023 Funded by ANR The existence of drug interactions in prescriptions is a risk for the patient and a reflection of improvable practices. These problems have already been
